As on Thursday, Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) got off with the flyer as it spiked 1.04% to $13.58, before settling in for the price of $13.44 at the close. Taking a more long-term approach, RDY posted a 52-week range of $12.50-$16.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 8.97% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 20.07%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -1.58%. This publicly-traded company’s shares outstanding now amounts to $834.42 million, simultaneously with a float of $833.09 million. The organization now has a market capitalization sitting at $11.31 billion. At the time of writing, stock’s 50-day Moving Average stood at $13.75, while the 200-day Moving Average is $14.99.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Drug Manufacturers – Specialty & Generic industry. Dr. Reddy’s Laboratories Ltd. ADR’s current insider ownership accounts for 0.00%, in contrast to 14.56% institutional ownership.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 19.05 per share during the current fiscal year.
Dr. Reddy’s Laboratories Ltd. ADR’s EPS decrease for this current 12-month fiscal period is -1.58% and is forecasted to reach 0.80 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -4.93% through the next 5 years, which can be compared against the 20.07% growth it accomplished over the previous five years trading on the market.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Trading Performance Indicators
Let’s observe the current performance indicators for Dr. Reddy’s Laboratories Ltd. ADR (RDY). It’s Quick Ratio in the last reported quarter now stands at 1.37. The Stock has managed to achieve an average true range (ATR) of 0.23. Alongside those numbers, its PE Ratio stands at $17.66, and its Beta score is 0.51. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.04. Similarly, its price to free cash flow for trailing twelve months is now 91.37.
In the same vein, RDY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.77, a figure that is expected to reach 0.21 in the next quarter, and analysts are predicting that it will be 0.80 at the market close of one year from today.
Technical Analysis of Dr. Reddy’s Laboratories Ltd. ADR (RDY)
Through scrutinizing the latest numbers posted by the [Dr. Reddy’s Laboratories Ltd. ADR, RDY], it can be observed that its last 5-days Average volume of 1.93 million was better the volume of 1.9 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 95.72% While, its Average True Range was 0.22.
Raw Stochastic average of Dr. Reddy’s Laboratories Ltd. ADR (RDY) in the period of the previous 100 days is set at 30.51%, which indicates a major fall in contrast to 96.86% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 20.93% that was lower than 25.02% volatility it exhibited in the past 100-days period.
